Understanding Named Patient Supply

Sponsored by: Mawdsley-Brooks

Focused on:

  • Named Patient Supply
  • Healthcare Providers

Date: 27 September


Time: 3PM London/10AM New York

Benefits and key considerations of an effective Named Patient Programme

Healthcare professionals worldwide are faced with the challenge of trying to treat patients who need a medicine that is not locally available to them, while patients themselves (via the internet and patients advocacy groups) are equally educated of any new medicine that might improve their condition.

The drug may not yet be launched in their country, been discontinued, or is simply in short supply. In these instances, physicians and pharmacists need to source and dispense patient specific, difficult-to-obtain treatment (often referred to as named patient medicines), often on an urgent basis.

Named patient supply is an increasingly important consideration for pharmaceutical and biotech companies seeking to enable regulatory compliant and ethical access for patients to new and innovative medicines.

In 2004, Mawdsleys started a dedicated business focused on providing fully managed and regulatory compliant access for physicians and patients to medicines that are not approved in the UK. Since then, Mawdsleys have expanded this service to offer the same access opportunities to patients worldwide though our operations in the EU, LATAM and MENA regions.

Join this webinar to develop a deeper understanding of how named patient programmes can be successfully implemented, key considerations of the healthcare providers, payers and the other stakeholders involved, regulatory landscape and raising awareness of such a programme in order to maximise its potential.

Presented by

Richard Leach,

Global Named Patient Program Manager

Richard has worked for variety of small to large pharmaceutical companies including a CRO and CMO in Project Management, Technology Evaluation, Sales & Marketing, and Distributor Management.

Richard has a 1st class Honours degree in Biotechnology and thesis titled “Intellectual Property Law in Biotechnology”.

Alain Zeitoun, MD,

Named Patient Programs Medical & Science Liaison

Dr Alain Zeitoun is managing Medical & Science Affairs for Named Patient Programs at the Mawdsleys Group UK since 2015.

He has held senior Medical and Marketing positions at Merck Sharp and Dohme (MSD), P&G Pharma and Boehringer Ingelheim pharmaceutical companies in France, Europe and Middle East for over 20 years. In all these positions, Dr Zeitoun was in charge of several therapeutic fields such as Cardiology, Dermatology, Gastroenterology Infectious Diseases, Neurology, Oncology, Orthopedics, Rheumatology and more.

Alain Zeitoun obtained his MD. Degree from Paris Medical School and his Business Degree from ESCP Europe Business School, Paris.

Michelle Biggs,

Mawdsleys Group Regulatory Affairs Manager + EU Responsible Person

Michelle has over 20 years of experience in the Pharmaceutical sector. During this time she has gained extensive knowledge in areas of both GMP and GDP.

Michelle is a registered Pharmacy Technician with the General Pharmaceutical Council.

Key Learning Objectives

  • Understanding what drives the demand for Named Patient medicines and the involvement of key stakeholders in the process
  • Recognise the regulatory expectations and challenges associated with the supply of medicines on a Named Patient basis
  • Raising awareness of a Named Patient programme in a regulatory compliant and ethical manner


  • Medical Affairs
  • Clinical Operations
  • Clinical Development
  • Research & Development
  • Market Access Managers
  • Supply Chain/Logistics Managers
  • Product Managers
  • Patient Advocacy
  • Business Development
  • Commercial Officer